Ontology highlight
ABSTRACT: Objectives
Disease-modifying therapies (DMTs) can slow disease progression in multiple sclerosis (MS). The objective of this study was to explore the cost-of-illness (COI) progression among newly diagnosed people with MS in relation to the first DMT received.Design and setting
A cohort study using data from nationwide registers in Sweden.Participants
People with MS (PwMS) in Sweden first diagnosed in 2006-2015, when aged 20-55, receiving first-line therapy with interferons (IFN), glatiramer acetate (GA) or natalizumab (NAT). They were followed up through 2016.Outcome measures
Outcomes (in Euros, €) were: (1) secondary healthcare costs: specialised outpatient and inpatient care including out-of-pocket expenditure, DMTs including hospital-administered MS thera
SUBMITTER: Karampampa K
PROVIDER: S-EPMC10193087 | biostudies-literature | 2023 May
REPOSITORIES: biostudies-literature